DDDilsher S. Dhoot

Dilsher S. Dhoot

*This is an algorithmically generated author record based on publicly available information.

Dilsher S. Dhoot has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE

    by Dilsher S. Dhoot, Lawrence J. Singerman, Philip J. Ferrone, Charles C. Wykoff, Roger A. Goldberg, Robyn H. Guymer, Esther L. Kim, Mathew W. Maccumber, André Maia, Song Yu, et al.


  • Open Access

    Effects of Time from Diagnosis to Treatment and Baseline Vision on Retinal Vein Occlusion Outcomes in Aflibercept 2 mg Phase III Trials

    by Sumit Sharma, Dilsher S. Dhoot, Dilraj S. Grewal, Eric Jung, Fabiana Q. Silva, Weiming Du, Hadi Moini, David S. Boyer

  • Open Access

    Efficacy of Continuous Pegcetacoplan Treatment for Subfoveal Geographic Atrophy in Age-Related Macular Degeneration: 36-Month Results from OAKS, DERBY, and GALE Open-Label Extension

    by Dilsher Dhoot, Sunir Garg, David Brown, Ivan Suñer, Ehsan Rahimy, David Boyer, Kineta Naidu, Chao Li, Caroline Baumal, Robyn Guymer

    To report efficacy of intravitreal pegcetacoplan treatment over 36 months in eyes with subfoveal geographic atrophy (GA). The GALE (NCT04770545) open-label extension trial adds 12 months of results to the 24-month Phase 3 OAKS (NCT03525613) and DERBY (NCT03525600) trials, representing up to 36 months of continuous pegcetacoplan treatment. They included a heterogeneous population of eyes with subfoveal GA (63%). Pegcetacoplan-treated eyes enrolling in GALE continued at the same interval of pegcetacoplan monthly (PM) or every other month (PEOM). Patients’ eyes in sham monthly or every-other-month arms crossed over to receive pegcetacoplan in GALE at the same interval (sham crossover). Consequently, projected sham, calculated from prior 24-month GA growth rate of sham-observed eyes in OAKS and DERBY averaged across four 6-month segments, was the comparator for the first 12 months of GALE (months 24–36). This analysis reports results of eyes with subfoveal GA at baseline. In eyes with subfoveal GA, 84% had best corrected visual acuity (BCVA) ≥20/200 and 38% had BCVA ≥20/63 at OAKS and DERBY baseline. Pegcetacoplan reduced subfoveal GA growth rate by 21% (p<0.0001) with PM and 19% (p=0.0001) with PEOM over 36 months. Increasing efficacy over time was noted between months 24 and 36; 31% reduction in subfoveal GA growth rate with PM and 25% reduction with PEOM (both p<0.0001) compared with projected sham. Microperimetry demonstrated significant reduction in formation of absolute scotomas with PM at 24 months (–2.5 number of scotomas formed; 95% confidence interval [CI]: –4.5, –0.4; p=0.0205) and 36 months (–4.0 number of scotomas formed; 95% CI: –6.8, –1.2; p=0.0050), compared to sham crossover in subfoveal GA. Safety profile in GALE was consistent with OAKS and DERBY. Long-term efficacy of pegcetacoplan in slowing GA progression was demonstrated over 36 months in eyes with subfoveal GA. Geographic atrophy (GA) is a progressive, permanent retinal degenerative disease that can lead to vision loss in patients over 60 years of age. This analysis was done to look at how pegcetacoplan, a treatment for GA, could help people with GA once it affected the center of their vision, called subfoveal GA. People with subfoveal GA are at risk of losing more of their central vision, which is important for reading, driving, and recognizing faces. Researchers looked at data from the GALE clinical trial, which followed people with GA for 3 years to see how well pegcetacoplan worked. They studied whether pegcetacoplan slowed down the growth of subfoveal GA and whether it helped lower the risk of forming new blind spots. People with subfoveal GA retained some vision that could be protected. In fact, 84% of them had mild or moderate visual impairment at baseline. Researchers found that pegcetacoplan slowed the growth of subfoveal GA over 3 years, whether it was given every month or every other month. They also found that pegcetacoplan may have lowered the risk of forming new blind spots in the eye. Pegcetacoplan treatment helped for people with subfoveal GA. Treating subfoveal GA is important because it can help people save the vision they still have and slow down further vision loss.


  • Open Access

    Anti-vascular endothelial growth factor dosing frequency and visual outcomes in macular oedema following branch retinal vein occlusion

    by Yasha S. Modi, Lediana Goduni, Hadi Moini, Andrea Gibson, Nick Boucher, Genevieve Lucas, Dilsher S. Dhoot

    Objectives: To determine the relationship between treatment frequency with intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes in eyes with macular oedema (MO) secondary to branch retinal vein occlusion (BRVO) in US clinical practice. Methods: Study eyes that initiated anti-VEGF injections between January 2012 and May 2016 were followed for ≥1 year in a retrospective analysis of medical records (Vestrum Health database). Eyes were analysed in 2 cohorts by treatment duration (years 1 and 2) and then in 2 subcohorts by injection frequency (≤6 or ≥7 injections/year). Results: Among 3099 eyes with MO secondary to BRVO, 1197 (38.6%) received ≤6 injections (mean injections, 4.6; baseline mean VA, 53 letters) and 1902 (61.4%) received ≥7 injections through 1 year (mean injections, 8.8; baseline mean VA, 52 letters). At year 1, mean VA gain from baseline was 10.4 versus 13.9 letters in eyes receiving ≤6 versus ≥7 injections (p < 0.001). At year 2, mean VA in eyes receiving ≤6 (n = 42) versus ≥7 injections (n = 227) was 64 versus 68 letters, respectively (p = 0.19). Mean VA change between the start and end of year 2 in eyes receiving ≥7 injections in year 1 and ≤6 in year 2 differed significantly from that of eyes receiving ≥7 injections in both years (–3.0 vs 0.7 letters, respectively; p < 0.001). Conclusions: In routine clinical practice, more frequent dosing with anti-VEGF agents was associated with greater visual benefits in eyes with MO secondary to BRVO.


  • Open Access

    Antivascular Endothelial Growth Factor Dosing Frequency and Visual Outcomes in Macular Edema Following Central Retinal Vein Occlusion

    by Yasha S. Modi, Lediana Goduni, Hadi Moini, Andrea Gibson, Nick Boucher, Genevieve Lucas, Dilsher S. Dhoot

    We evaluated the relationship between dosing frequency of intravitreal antivascular endothelial growth factor (anti-VEGF) agents and visual acuity (VA) outcomes over 2 years in eyes with macular edema (ME) secondary to central retinal vein occlusion (CRVO) in the US routine clinical practice setting. This retrospective analysis assessed electronic medical records of eyes with ME secondary to CRVO that received their first anti-VEGF injection January 1, 2012, to May 31, 2016, and were followed for 1 year or more in the US-based Vestrum Health Treatment and Outcomes database. Eyes were divided into 2 injection frequency subcohorts (≤6 or ≥7 injections/year). Overall, 851 (34.6%) of 2458 eyes with ME secondary to CRVO received 6 or fewer injections, and 1607 (65.4%) received 7 or more injections through 1 year. The mean number of injections in patients receiving 6 or fewer injections and 7 or more injections was 4.7 and 8.8, respectively, and baseline mean VA was 35 and 37 letters, respectively. At year 1, mean letter gain from baseline was less in eyes receiving 6 or fewer injections vs in those receiving 7 or more injections (7.0 vs 12.2, P < .001). Mean VA at year 2 was 50 letters in eyes receiving 6 or fewer injections (n = 50) and 55 letters in eyes receiving 7 or more injections (n = 157). In routine clinical practice, more frequent dosing with anti-VEGF agents was associated with greater visual benefits in eyes with ME secondary to CRVO.


  • Open Access

    Baseline Factors Associated with Diabetic Retinopathy Improvement in RIDE/RISE

    by Dilsher S. Dhoot, Lauren F. Hill, Avanti Ghanekar, Kathleen Wade Tarnowski, Ferhina S. Ali


  • Private Equity's Game Plan and Why it Should Matter to Us

    by Veeral Sheth, Dilsher Dhoot, Seenu M. Hariprasad

    Ophthalmic Surgery, Lasers and Imaging Retina | Seenu M. Hariprasad Practical Retina Co-Editor For this column, Veeral Sheth, MD, MBA, and Dilsher Dhoot, MD, were asked to comment on the implications of penetration of private equity (PE) into the retina landscape. During the last decade we have seen an accelerating trend of PE deals in ophthalmology. Where is the


  • Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy

    by Dilsher S. Dhoot, Robert L. Avery

    The prevalence of diabetes is growing at epidemic rates in the USA. Diabetic retinopathy develops in a large proportion of patients and is a leading cause of blindness worldwide. Systemic management of diabetic retinopathy has included glycemic, hypertension, and lipid control. Local ophthalmic treatment in the form of focal/grid or panretinal laser photocoagulation has been shown to prevent vision loss in diabetic edema and proliferative diabetic retinopathy, respectively. The introduction of anti-vascular endothelial growth factor for diabetic macular edema and retinopathy has provided clinicians with improved clinical outcomes with potentially less damaging effects than laser.


  • Open Access

    Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study)

    by D S Dhoot, D J Pieramici, M Nasir, A A Castellarin, S Couvillion, R F See, N Steinle, M Bennett, M Rabena, R L Avery

    To compare the efficacy of ranibizumab 0.5-mg and 2.0-mg intravitreal injections for persistent diabetic macular edema (DME) previously treated with bevacizumab. In all, 43 patients with residual center-involved DME following intravitreal bevacizumab were included in this 12-month prospective, nonrandomized, multicenter study. Enrolled patients received three monthly ranibizumab 0.5-mg injections. At month 3, patients with residual macular edema switched to three monthly injections of ranibizumab 2.0-mg. Assessments included monthly visual acuity and spectral-domain optical coherence tomography. Mean visual acuity improved by +6.4 letters at month 3 and +8.8 letters at month 6. Mean central subfield thickness (CST) decreased by –113 μm at month 3 and –165 μm at month 6. Before enrollment, 29/43 (67.4%) patients showed 10% reduction in CST, whereas 6 showed 10% reduction in CST after switching to three monthly ranibizumab 2.0-mg doses. No serious adverse events were observed to month 6. Ranibizumab 0.5-mg or 2.0-mg may improve visual and anatomic outcomes in patients with DME who demonstrated minimal or no response to bevacizumab therapy. Moreover, increased dosage of ranibizumab (2.0-mg) may provide additional benefit over ranibizumab 0.5-mg in some patients. However, 2.0-mg ranibizumab is not currently commercially licensed or available.